Alternativní vyhledávání:
harm » farm (Rozšířit vyhledávání)
revolvesdsds. » resolvesdsds. (Rozšířit vyhledávání), evolveddsds. (Rozšířit vyhledávání), resolvedsds. (Rozšířit vyhledávání)
revolves. » resolves. (Rozšířit vyhledávání), evolved. (Rozšířit vyhledávání), resolve. (Rozšířit vyhledávání)
Zobrazuji výsledky 1 - 20 z 142 pro vyhledávání 'harm is (((((resolved. OR involves.) OR involves.) OR revolvesdsds.) OR involved.) OR revolves.)', doba hledání: 0,11 s. Upřesnit hledání
  1. 1
    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl

    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl Autor Elham Mazarei (4508746)

    Vydáno 2025
    Témata:
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB).

    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB). Autor Zhizhong Wang (838758)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year).

    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year). Autor Olga Amberger (20299807)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  6. 6
    LOESS curves of participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year).

    LOESS curves of participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year). Autor Olga Amberger (20299807)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwater within the Tongde Basin.

    Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwate... Autor Shanhu Xiao (22226759)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  16. 16
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  19. 19
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. Autor Diana M. Hendrickx (1507435)

    Vydáno 2025
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: